Roth Capital Lifts PT on Ligand (LGND) to $92; Still Sees Plenty of Positive Catalysts Ahead

February 12, 2014 7:23 AM

Roth Capital reaffirms Ligand Pharmaceuticals (Nasdaq: LGND) at Buy, but lifts its price target from $69 up to $92.

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found